BioVectra Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)
BioVectra Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD active pharmaceutical ingredients (APIs) for clinical and commercial applications.
BioVectra’s efficient cGMP CBD manufacturing process allows for the production of hundreds of kilograms, with the ability to scale-up to multi-metric ton quantities. This scale-up and supporting regulatory experience is a key competency for BioVectra, which can be applied to additional cannabinoid derivatives. Production is on-going for intermediate-scale batches, with process validation and submission of a Drug Master File to follow.
Located in Canada, BioVectra is uniquely positioned as a global
supplier of synthetic cGMP CBD. The company can offer material supply,
as well as product storage services as required.
BioVectra has a history of working in cannabinoids, dating back to
the early 2000s, when it developed a supply of dronabinol. Building off
its existing strengths in complex synthetic chemistry and natural
product purifications, the company’s ability to manufacture synthetic
cGMP CBD complements increased market demand. BioVectra looks forward to
continuing to supply its current and new customers with this
pharmaceutically important compound.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance